Rigel Pharmaceuticals (NASDAQ: RIGL) is one of 288 public companies in the “Bio Therapeutic Drugs” industry, but how does it contrast to its peers? We will compare Rigel Pharmaceuticals to similar businesses based on the strength of its institutional ownership, valuation, profitability, dividends, earnings, risk and analyst recommendations.

Earnings & Valuation

This table compares Rigel Pharmaceuticals and its peers gross revenue, earnings per share and valuation.

Gross Revenue EBITDA Price/Earnings Ratio
Rigel Pharmaceuticals $10.34 million -$67.71 million -3.58
Rigel Pharmaceuticals Competitors $464.68 million $167.54 million -6.58

Rigel Pharmaceuticals’ peers have higher revenue and earnings than Rigel Pharmaceuticals. Rigel Pharmaceuticals is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.


This table compares Rigel Pharmaceuticals and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Rigel Pharmaceuticals -354.14% -105.86% -82.23%
Rigel Pharmaceuticals Competitors -4,765.60% -486.43% -44.98%

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Rigel Pharmaceuticals and its peers, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Rigel Pharmaceuticals 0 0 4 0 3.00
Rigel Pharmaceuticals Competitors 1377 4464 12274 311 2.63

Rigel Pharmaceuticals presently has a consensus price target of $6.75, indicating a potential upside of 173.28%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 34.40%. Given Rigel Pharmaceuticals’ stronger consensus rating and higher probable upside, analysts plainly believe Rigel Pharmaceuticals is more favorable than its peers.

Insider & Institutional Ownership

88.2% of Rigel Pharmaceuticals shares are owned by institutional investors. Comparatively, 51.6% of shares of all “Bio Therapeutic Drugs” companies are owned by institutional investors. 5.2% of Rigel Pharmaceuticals shares are owned by insiders. Comparatively, 17.4% of shares of all “Bio Therapeutic Drugs” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Volatility & Risk

Rigel Pharmaceuticals has a beta of 1.24, meaning that its share price is 24% more volatile than the S&P 500. Comparatively, Rigel Pharmaceuticals’ peers have a beta of 6.57, meaning that their average share price is 557% more volatile than the S&P 500.

About Rigel Pharmaceuticals

Rigel Pharmaceuticals, Inc. is a clinical-stage biotechnology company. The Company is engaged in the discovering, developing and providing novel small molecule drugs that improve the lives of patients with immune and hematological disorders, cancer and rare diseases. The Company’s pioneering research focuses on signaling pathways that are critical to disease mechanisms. The Company’s clinical programs include clinical trials of fostamatinib, an oral spleen tyrosine kinase (SYK) inhibitor, in a number of indications. The Company has submitted a new drug application (NDA) to the United States food and drug administration (FDA) for fostamatinib in patients with chronic or persistent immune thrombocytopenia (ITP). In addition, the Company has product candidates in development with partners BerGenBio AS, Daiichi Sankyo and Aclaris Therapeutics. The Company is engaged in conducting research in the disease areas of inflammation/immunology and muscle wasting/muscle endurance.

Receive News & Stock Ratings for Rigel Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rigel Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.